Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Mind Medicine Inc (MNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MNMD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 39.3% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 449.95M USD | Price to earnings Ratio - | 1Y Target Price 24.5 |
Price to earnings Ratio - | 1Y Target Price 24.5 | ||
Volume (30-day avg) 1500407 | Beta 2.4 | 52 Weeks Range 5.03 - 11.36 | Updated Date 04/2/2025 |
52 Weeks Range 5.03 - 11.36 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.44% | Return on Equity (TTM) -68.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 198062103 | Price to Sales(TTM) - |
Enterprise Value 198062103 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.57 | Shares Outstanding 75368400 | Shares Floating 70192060 |
Shares Outstanding 75368400 | Shares Floating 70192060 | ||
Percent Insiders 1.49 | Percent Institutions 55.79 |
Analyst Ratings
Rating 4.5 | Target Price 8 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mind Medicine Inc
Company Overview
History and Background
Mind Medicine (MindMed) Inc. was founded in 2019. It is a biopharmaceutical company developing psychedelic-derived therapies for mental health disorders. The company went public in 2020, focusing on research and development of drug candidates.
Core Business Areas
- Drug Development: Focuses on developing psychedelic-inspired medicines for various mental health and addiction disorders.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Digital Therapeutics: Exploring digital technologies to enhance treatment outcomes.
Leadership and Structure
Robert Barrow serves as the CEO. The company operates with a structured management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- MM-120 (LSD):: An investigational drug for generalized anxiety disorder (GAD). Currently in Phase 3 trials. No current market share, as not yet approved. Competitors include traditional anxiety medications and other psychedelic therapy developers.
- MM-402 (R-MDMA):: An investigational drug for autism spectrum disorder (ASD). In clinical development. No current market share, as not yet approved. Competitors include traditional ASD management strategies and other emerging therapies.
Market Dynamics
Industry Overview
The mental health therapeutics market is large and growing, with increasing acceptance of psychedelic therapies. There is a growing need for better treatments for mental health disorders and a surge of interest in alternative therapies.
Positioning
MindMed is positioned as a leading biopharmaceutical company in the psychedelic medicine space, focusing on scientifically rigorous clinical trials and drug development. The company faces competition from other psychedelic therapy companies and established pharmaceutical firms.
Total Addressable Market (TAM)
The global mental health market is estimated at hundreds of billions of dollars. The TAM for psychedelic-assisted therapies is a subset of this, estimated to grow significantly in the coming years. MindMed is positioned to capture a share of this growing market if its therapies are approved.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced management team
- Advanced clinical trial programs
- Focus on scientific rigor
Weaknesses
- High cash burn rate
- Regulatory risks associated with psychedelic drugs
- Dependence on clinical trial success
- Limited revenue stream
Opportunities
- Potential for breakthrough therapies for mental health disorders
- Growing acceptance of psychedelic medicine
- Partnerships with research institutions and pharmaceutical companies
- Expansion into new indications and markets
Threats
- Competition from other psychedelic therapy companies
- Unfavorable regulatory changes
- Clinical trial failures
- Negative public perception of psychedelic drugs
Competitors and Market Share
Key Competitors
- GHRS
- ATAI
- CYBN
- COMP
Competitive Landscape
MindMed faces strong competition. Many companies are developing novel mental health treatments.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial milestones.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its drug candidates. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include advancing MM-120 into Phase 3 trials and expanding its research pipeline.
Summary
MindMed is a biopharmaceutical company focusing on developing psychedelic-inspired medicines. It has advanced clinical trials but carries inherent risk of drug development, regulatory uncertainty, and high cash burn. Success relies on clinical trial results and market adoption of its therapies.
Similar Companies
ATAI
ATAI Life Sciences BV
ATAI
ATAI Life Sciences BV
COMP
Compass Inc
COMP
Compass Inc
CYBN
Cybin Inc
CYBN
Cybin Inc
GHRS
GH Research PLC
GHRS
GH Research PLC
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mind Medicine Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-03-03 | CEO & Director Mr. Robert Barrow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.mindmed.co |
Full time employees 74 | Website https://www.mindmed.co | ||
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.